Mark DeLong
Corporate Officer/Principal en APELLIS PHARMACEUTICALS, INC. .
Fortuna: 3 M $ al 30/04/2024
Perfil
Mark DeLong is currently the Chief Business & Strategy Officer at Apellis Pharmaceuticals, Inc. He previously worked at EMD Serono, Inc. as the Head of Business Development from 2007 to 2018.
Mr. DeLong completed his undergraduate degree at The Pennsylvania State University and holds an MBA from the University of Michigan.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 18/03/2024 | 54 693 ( 0.05% ) | 3 M $ | 30/04/2024 |
Cargos activos de Mark DeLong
| Empresas | Cargo | Inicio |
|---|---|---|
| APELLIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/02/2018 |
Antiguos cargos conocidos de Mark DeLong.
| Empresas | Cargo | Fin |
|---|---|---|
EMD Serono, Inc.
 EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Corporate Officer/Principal | 01/01/2018 |
Formación de Mark DeLong.
| The Pennsylvania State University | Undergraduate Degree |
| University of Michigan | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| APELLIS PHARMACEUTICALS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Mark DeLong
